Initially, Interius will use the funding to treat hematologic malignancies by leveraging its platform to generate chimeric antigen receptor (CAR) T cells in vivo. This method bypasses the need for ex vivo manipulations and potentially toxic preconditioning chemotherapy required for standard CAR T-cell treatments. The company is focused on immuno-oncology indications that are not amenable to current gene therapy modalities.

The oversubscribed series A financing was co-led by Cormorant Asset Management and Fairmount Funds.